thyssenkrupp nucera Returns to Profit Despite Sales Decline in 2024/2025 Fiscal Year

Based on preliminary unaudited figures, thyssenkrupp nucera reported a return to profitability in the 2024/2025 fiscal year despite facing challenging market conditions and a slight decline in sales. The world's leading provider of electrolysis technologies achieved earnings before interest and taxes (EBIT) of approximately EUR 2 million, a significant improvement from the negative EUR 14 million reported in the previous fiscal year. Sales reached EUR 845 million, slightly below the previous year's EUR 862 million but demonstrating stable operational performance amid market headwinds.

The company's performance exceeded expectations in some areas while falling short in others. While sales came in slightly below the forecasted range of EUR 850 million to EUR 920 million, EBIT landed in the upper half of the projected range between EUR -7 million and EUR 7 million. The company maintained positive free cash flow and continued to finance its operations through its business activities, indicating strong financial resilience despite market challenges.

Segment performance revealed contrasting trends between thyssenkrupp nucera's two main business areas. The Green Hydrogen (gH2) segment, which utilizes alkaline water electrolysis technology to produce climate-neutral hydrogen, experienced a decline in sales to EUR 459 million from EUR 524 million in the previous year. However, this segment showed significant improvement in EBIT, reducing losses from EUR -76 million to EUR -56 million. In contrast, the Chlor-Alkali (CA) segment demonstrated strong growth with sales increasing by double digits to EUR 386 million from EUR 338 million, though EBIT slightly declined to EUR 58 million from EUR 62 million.

Order intake patterns reflected the challenging market environment, with total orders dropping to EUR 348 million from EUR 636 million in the previous fiscal year. The gH2 segment accounted for only EUR 26 million of these orders compared to EUR 356 million previously, while the CA segment increased its order intake to EUR 322 million from EUR 279 million. The order backlog as of September 30, 2025, stood at EUR 0.6 billion, down from EUR 1.1 billion in the previous year. Detailed explanations of the financial performance indicators used can be found in thyssenkrupp nucera's 2023/2024 Annual Report available at https://www.thyssenkrupp-nucera.com.

Looking ahead to the 2025/2026 fiscal year, the Management Board anticipates further challenges, projecting consolidated sales between EUR 500 million and EUR 600 million and EBIT ranging from EUR -30 million to EUR 0 million. CEO Dr. Werner Ponikwar attributed the expected decline to increasingly challenging market conditions for green hydrogen, including continued restraint in final investment decisions and a deteriorating global economic environment. The company has already initiated measures to reduce the impact of lower sales on cost coverage and consolidated earnings.

The company's strategic positioning in both hydrogen and chlor-alkali markets, combined with strong financial resilience, positions thyssenkrupp nucera to navigate current market challenges while continuing to pursue long-term strategic goals. The full detailed results for Q4/FY 2024/2025 and the complete sales and earnings forecast for fiscal year 2025/2026 will be published in the 2024/2025 Annual Report on December 17, 2025. The company maintains its position as a key player in the global transition to clean energy through its world-leading electrolysis technologies and extensive project experience spanning more than 600 installations with over 10 gigawatts of capacity.